Revvity, Inc. (RVTY)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 3,783 | 3,828 | 3,312 | 2,751 | 2,755 | 2,856 | 2,912 | 2,851 |
| Operating profit | $m | 357 | 359 | ||||||
| Net profit | $m | 728 | 943 | 569 | -118 | 296 | 242 | 238 | 608 |
| EPS reported | $ | 2.08 | 2.10 | ||||||
| Operating cashflow per share | $ | 5.14 | 5.63 | ||||||
| Capex per share | $ | 0.65 | 0.62 | ||||||
| FCF per share | $ | 4.49 | 5.01 | ||||||
| Free cash flow | $m | 508 | 559 | ||||||
| Net debt | $m | 2,448 | 2,182 | ||||||
| Book value equity | $m | 7,250 | 7,229 | ||||||
| Book value per share | $ | 64.04 | 64.69 | ||||||
| Number of shares | m | 113.21 | 111.75 | ||||||
| DPS (TTM paid) | $ | 0.28 | 0.35 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 46.51 | 71.96 | ||||||
| P/B LTM | x | 1.52 | 1.52 | ||||||
| P/S LTM | x | 3.85 | 3.78 | ||||||
| P/FCF LTM | x | 21.63 | 19.66 | ||||||
| EV/EBITDA LTM | x | 20.51 | 17.72 | ||||||
| EV/Sales LTM | x | 4.76 | 5.27 | ||||||
| Earnings Yield LTM | % | +2.15% | +1.39% | ||||||
| FCF Yield | % | +4.62% | +5.09% | ||||||
| Quality | |||||||||
| ROE | % | +3.33% | +3.27% | ||||||
| ROIC | % | +2.82% | +2.91% | ||||||
| Operating margin | % | +12.49% | +12.32% | ||||||
| Gross margin | % | +53.08% | +52.11% | ||||||
| FCF/Sales | % | +17.80% | +19.21% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -13.69% | -12.86% | ||||||
| Sales Growth YoY | % | +3.67% | +5.69% | ||||||
| Net Income Growth YoY | % | -18.31% | -19.70% | ||||||
| FCF Growth | % | -6.17% | +3.27% | ||||||
| Operating Profit Growth | % | -13.13% | -12.59% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +0.30% | +0.24% | ||||||
| Dividend Growth | % | 0.00% | +25.00% | ||||||
| Payout Ratio | % | +13.93% | +13.30% | ||||||
| FCF/Debt | x | 0.14 | 0.17 | ||||||
| Net Debt/EBITDA | x | 3.92 | 3.02 | ||||||
| EBIT/Net interest | x | 3.87 | 3.82 | ||||||
| Net debt/market cap | % | +30.64% | +24.59% | ||||||
| Net debt/Equity | x | 0.34 | 0.30 | ||||||
| Gross debt/equity | x | 0.48 | 0.46 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free